Published in Biomed Res Int on January 01, 2015
The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol (2016) 0.93
mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia. Mol Pain (2015) 0.83
Intrathecal rapamycin attenuates morphine-induced analgesic tolerance and hyperalgesia in rats with neuropathic pain. Transl Perioper Pain Med (2015) 0.77
Activation of the Mammalian Target of Rapamycin in the Rostral Ventromedial Medulla Contributes to the Maintenance of Nerve Injury-Induced Neuropathic Pain in Rat. Neural Plast (2015) 0.75
Regulation of transient receptor potential cation channel subfamily V1 protein synthesis by the phosphoinositide 3-kinase/Akt pathway in colonic hypersensitivity. Exp Neurol (2017) 0.75
Potential mechanisms of microRNA-141-3p to alleviate chronic inflammatory pain by down-regulation of downstream target gene HMGB1: In vitro and in vivo studies. Gene Ther (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
TOR signaling in growth and metabolism. Cell (2006) 35.29
mTOR signaling in growth control and disease. Cell (2012) 29.21
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18
Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain (2009) 7.11
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J (2008) 6.32
Animal models of nociception. Pharmacol Rev (2001) 5.76
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62
The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature (2012) 5.61
Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem J (1993) 5.53
mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci (2009) 5.04
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res (2009) 4.50
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J (2009) 4.12
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6 kinase. J Biol Chem (2005) 3.56
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol (2008) 3.50
Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell (2010) 3.33
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res (2009) 3.03
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 2.80
Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation. Curr Opin Genet Dev (1999) 2.48
Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science (1999) 2.43
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22
Rapamycin inhibits mTORC1, but not completely. Autophagy (2009) 1.99
Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. J Neurosci (2007) 1.95
Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci (2010) 1.92
Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther (2007) 1.90
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med Chem Lett (2010) 1.89
Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res (2010) 1.86
A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res (2008) 1.81
Pathological pain and the neuroimmune interface. Nat Rev Immunol (2014) 1.73
Local translation in primary afferent fibers regulates nociception. PLoS One (2008) 1.70
A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci (2009) 1.58
Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol (2011) 1.54
When does acute pain become chronic? Br J Anaesth (2010) 1.48
Alleviating suffering 101--pain relief in the United States. N Engl J Med (2012) 1.47
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther (2011) 1.45
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol (2012) 1.40
Arrest of myelination and reduced axon growth when Schwann cells lack mTOR. J Neurosci (2012) 1.39
Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem (2012) 1.33
Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain (2011) 1.32
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett (2013) 1.31
Neuropathic pain: mechanisms and their clinical implications. BMJ (2014) 1.29
Spinal phosphinositide 3-kinase-Akt-mammalian target of rapamycin signaling cascades in inflammation-induced hyperalgesia. J Neurosci (2011) 1.26
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther (2011) 1.25
Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain (2009) 1.24
ATP-competitive inhibitors of mTOR: an update. Curr Med Chem (2011) 1.21
Formalin-induced behavioural hypersensitivity and neuronal hyperexcitability are mediated by rapid protein synthesis at the spinal level. Mol Pain (2009) 1.19
Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. Cancer Res (2013) 1.16
Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem (2006) 1.15
Expression and distribution of mTOR, p70S6K, 4E-BP1, and their phosphorylated counterparts in rat dorsal root ganglion and spinal cord dorsal horn. Brain Res (2010) 1.12
Opioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesia. J Clin Invest (2014) 1.11
Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation. Neuroscience (2010) 1.10
Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat. J Pain (2010) 1.09
mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. Pain (2013) 1.06
mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia (2012) 1.02
Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy (1998) 1.01
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol Pharm Bull (2009) 1.01
Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Paediatr Drugs (2012) 0.99
mTOR: a link from the extracellular milieu to transcriptional regulation of oligodendrocyte development. ASN Neuro (2013) 0.99
Intercellular communication in sensory ganglia by purinergic receptors and gap junctions: implications for chronic pain. Brain Res (2012) 0.98
Systemic inhibition of the mammalian target of rapamycin (mTOR) pathway reduces neuropathic pain in mice. Pain (2011) 0.98
Pain hypersensitivity mechanisms at a glance. Dis Model Mech (2013) 0.98
Axonal protein synthesis: a potential target for pain relief? Curr Opin Pharmacol (2011) 0.97
Translational investigation and treatment of neuropathic pain. Mol Pain (2012) 0.95
Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis. J Neuroimmunol (2012) 0.95
The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg Med Chem Lett (2009) 0.92
Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord (2003) 0.91
Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase. Bioorg Med Chem Lett (2013) 0.88
Characterization of the cloned full-length and a truncated human target of rapamycin: activity, specificity, and enzyme inhibition as studied by a high capacity assay. Biochem Biophys Res Commun (2005) 0.88
Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity. Protein Cell (2014) 0.88
mTOR and its downstream pathway are activated in the dorsal root ganglion and spinal cord after peripheral inflammation, but not after nerve injury. Brain Res (2013) 0.87
Akt/mTOR signalling in myelination. Biochem Soc Trans (2013) 0.85
Enlargement of the receptive field size to low intensity mechanical stimulation in the rat spinal nerve ligation model of neuropathy. Exp Neurol (2000) 0.84
The use of metformin is associated with decreased lumbar radiculopathy pain. J Pain Res (2013) 0.83
Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1β pro-inflammatory effects. J Neuroimmunol (2011) 0.83
Activation of mTOR in the spinal cord is required for pain hypersensitivity induced by chronic constriction injury in mice. Pharmacol Biochem Behav (2013) 0.82
Schwann cell autophagy counteracts the onset and chronification of neuropathic pain. Pain (2013) 0.82
Docking proteins. FEBS J (2010) 0.81